Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.
days to go:
Expired
investment:
£1,048,396
Studio Pictures Limited is a UK based production company that specialises in the development of high-quality British film and TV projects. The company's interest predominantly lies within the British film and television industry that can be created within budget ranging from £1 million - £15 million. The company has established relationships with studio houses such as Warner Bros., Sony Pictures and Lionsgate and aims to build upon projects that can be made into a franchise. Their production, A Steet Cat Named Bob, went on to be distributed by Sony Pictures in the UK and had a Royal Premiere in London. Studio Pictures Limited will consider putting up to a maximum of 20% of the budget for each project as equity, on a case by case basis, subject to company reserves. With the proceeds, the company will grow and scale the business. It will become a tenant at Twickenham Studios in West London and look to profitable emerging markets, i.e. streaming, animation and interactive movies to become one of the leading UK production companies.
days to go:
Expired
investment:
Withheld
The Best dot dot is a positive review website that lets individuals celebrate the good things in life and in turn, enables others to benefit from those experiences. The company aims to create a leading platform, with a large, engaged user base and ultimately to maximise shareholder value. The company has a full robust technology infrastructure and platform in place, consisting of a mix of unique in house technology and tried and tested industry-standard platforms. Significant work has already been done to create the IP that will be purchased by the company and the funds raised will be used to build on the work already done and to take the business to the next level. By increasing the user base, the revenue will rapidly increase as the company introduces additional revenue streams.
days to go:
Expired
investment:
£19,050
Evolution Biotechnologies (EB) is a company that aims to bring technologies of biological control from their proven uses in agriculture into high-need and high-value biomedical markets. The company aims to curtail the spread of the house dust mite, a key cause of asthma, through its patented device. Its room treatment kit for domestic or commercial use contains natural agents that target the house dust mite in a highly specific way. The company anticipates that this method will be able to exert widespread, stable control across a whole room from limited initial applications, following a standard agricultural practice. EB expects a potential market size of $2 billion per annum in China, the UK, Europe, and the United States for its product. It is seeking an investment of £2 million to bring the aforementioned product to field trials.
days to go:
Expired
investment:
Withheld
A sports platform where the user can invest, trade and support their favourites clubs and athletes. The Globatalent platform gives everyone the chance to invest in top prospect sports athletes and organisations from around the globe. Globatalent’s potential market of sports fans is vast, covering 97% of the world’s population. The Globatalent platform has already been built, tested, launched and is generating revenue since Feb 2019. Currently, the platform is managing a total of £1.2m in assets. With the proceeds, they are going to spend on marketing, technology, increase the customer base and cover the day-to-day operational costs.
days to go:
Expired
investment:
£420,931
PopUp Painting (PUP) is an art company that aims to be the leader in organising experiential social painting events in the UK. The company endeavours to bring art out of the classroom and gallery into the places people meet on an everyday basis, thereby, unleashing creativity. PUP has hosted over 45,000 guests to date. Total revenues to date are £1.1 million. In the last financial year, the company generated revenues of £373,000. The COVID-19 pandemic in March led to PUP launching its online art sessions which was met with positive feedback. The company resumed hosting in-person COVID-secure events from July 2020 onwards. PUP is seeking £175,000 at a pre-money valuation of £1.3 million to launch its own Central London experiential events space and to expand its current services to reach a new product market.
days to go:
Expired
investment:
Withheld
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.
days to go:
Expired
investment:
Withheld
The Ticket Bank (TTB) is an online ticketing marketplace that provides event tickets to disadvantaged and marginalised individuals free of charge. The company is powered by 'Tickets for Good'. It works with event organisers, charities, and community organisations to distribute otherwise unused event tickets to beneficiaries, creating unique life experiences that provide wide-ranging benefits to the health and wellbeing of its target audience. The platform already supports over 500+ charity partners who can choose tickets from over 50 venues/entertainment partners. The company introduced the 'Virtual Ticket Bank' and 'The Giving Back campaign' in the COVID-19 pandemic wherein it is sourcing thousands of tickets for National Health Service (NHS) and frontline care workers to express its gratitude for their services. They can use these tickets when the lockdown is over. The company will use the investment to create the integrations and data gathering tools to rapidly grow its channels, as well as, create additional value for both its charity and venue clients.
days to go:
Expired
investment:
£145,246
The SidebySide Partnership is a London based Enterprise Investment Scheme (EIS) Venture Capital (VC) firm. Its purpose is to finance and control the management teams of its investee companies enabling them to become a developed corporate entity. The SidebySide Partnership's focus is on fast-growing technology businesses with £1 - 10 million in revenue. It provides 100% EIS relief on investment with zero initial/ongoing fees charged to investors. The SidebySide Partnership's investment experience of 20+ corporate acquisitions totalling more than $200 million, 20+ private investments, and a rate of interest of 12x over the last 35 years has enabled it to become a dependable platform for upcoming tech businesses. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£1,500,000
